PE20010283A1 - Composicion que comprende interferon alfa pegilado y un antagonista ccr5 - Google Patents
Composicion que comprende interferon alfa pegilado y un antagonista ccr5Info
- Publication number
- PE20010283A1 PE20010283A1 PE2000000408A PE0004082000A PE20010283A1 PE 20010283 A1 PE20010283 A1 PE 20010283A1 PE 2000000408 A PE2000000408 A PE 2000000408A PE 0004082000 A PE0004082000 A PE 0004082000A PE 20010283 A1 PE20010283 A1 PE 20010283A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alpha
- phenyl
- heteroaryl
- pegilated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE AL USO 0,1µg/Kg A 9µg/Kg DE UN INTERFERON-ALFA PEGILADO TAL COMO INTERFERON ALFA-2a PEGILADO, INTERFERON ALFA-2b PEGILADO Y UN ANTAGONISTA CCR5 DE FORMULA I, II, ENTRE OTRAS; DONDE X ES C(R13), C(R13)(R19), C(O), O, NH, ENTRE OTROS; R ES R6-FENILO, R6-PIRIDILO, R6-TIOFENILO, R6-NAFTILO; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6; R2 ES R7,R8,R9-HETEROARILO, R9,R10,R11-N-OXIDO DE HETEROARILO; R3 ES R6-FENILO, R6-HETEROARILO, R6-NAFTILO; R5 Y R11 SON H, ALQUILO C1-C6; R6 ES H, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, CF3, ENTRE OTROS; R7 Y R8 SON ALQUILO C1-C6, HALOGENO, OH, CF3, OCH3, O-ACILO, OCF3; R9 ES R7, H, FENILO, NO2, CN, CH2F, CHO, -CH=NOR20, PIRIDILO, ENTRE OTROS; R13, R14, R15, R16 SON H, ALQUILO C1-C6; R19 ES R6-FENILO, R6-HETEROARILO, ENTRE OTROS; Xa ES C(R13)2, C(R13)(R19), CO, O, NH, ENTRE OTROS. TAMBIEN SE REFIERE AL USO CON 8 mg/Kg A 15 mg/Kg DE RIBAVIRINA, IL-2, IL-12, PENTAFUSIDA, TERAPIAS ANTIRETROVIRALES ALTAMENTE ACTIVAS (HARRT); PUDIENDO SER UTIL EN PACIENTES PEDIATRICOS QUE HAN O NO HAN SIDO SOMETIDOS A TRATAMIENTO; COINFECTADOS CON HIV-1 Y HCV
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30489799A | 1999-05-04 | 1999-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010283A1 true PE20010283A1 (es) | 2001-03-16 |
Family
ID=23178462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000408A PE20010283A1 (es) | 1999-05-04 | 2000-05-02 | Composicion que comprende interferon alfa pegilado y un antagonista ccr5 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1175224B1 (es) |
| JP (1) | JP2002543144A (es) |
| CN (1) | CN1349408A (es) |
| AR (1) | AR023824A1 (es) |
| AT (1) | ATE289516T1 (es) |
| AU (1) | AU776541B2 (es) |
| BR (1) | BR0010593A (es) |
| CA (1) | CA2365900A1 (es) |
| DE (1) | DE60018273T2 (es) |
| ES (1) | ES2238277T3 (es) |
| HK (1) | HK1039278B (es) |
| HU (1) | HUP0202734A3 (es) |
| MX (1) | MXPA01011116A (es) |
| MY (1) | MY127670A (es) |
| NO (1) | NO328679B1 (es) |
| NZ (1) | NZ514519A (es) |
| PE (1) | PE20010283A1 (es) |
| PT (1) | PT1175224E (es) |
| TW (1) | TWI289454B (es) |
| WO (1) | WO2000066141A2 (es) |
| ZA (1) | ZA200108870B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
| TW201018661A (en) | 2003-03-14 | 2010-05-16 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
| JPWO2004092136A1 (ja) * | 2003-04-18 | 2006-07-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
| WO2004092169A1 (ja) | 2003-04-18 | 2004-10-28 | Ono Pharmaceutical Co., Ltd. | スピロピペリジン化合物およびその医薬用途 |
| DE602005002673T2 (de) | 2004-04-29 | 2008-07-24 | F. Hoffmann-La Roche Ag | Nukleotidsequenzvariation im Gen NS5A als Marker |
| MX2007002886A (es) | 2004-09-13 | 2007-05-16 | Ono Pharmaceutical Co | Derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo. |
| KR20070107085A (ko) * | 2005-02-23 | 2007-11-06 | 쉐링 코포레이션 | 케모카인 수용체의 억제제로서 유용한 피페리디닐 피페라진유도체 |
| EP1889622A4 (en) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
| PL1942108T3 (pl) | 2005-10-28 | 2014-03-31 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową i jego zastosowanie |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| CN101443322A (zh) | 2006-03-10 | 2009-05-27 | 小野药品工业株式会社 | 含氮杂环衍生物及含有该衍生物作为活性成分的药物 |
| WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| US10272143B2 (en) * | 2014-01-08 | 2019-04-30 | Immunovative Therapies Ltd. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| WO1997016204A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| WO1998025617A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
-
2000
- 2000-05-01 HU HU0202734A patent/HUP0202734A3/hu unknown
- 2000-05-01 ES ES00928604T patent/ES2238277T3/es not_active Expired - Lifetime
- 2000-05-01 CA CA002365900A patent/CA2365900A1/en not_active Abandoned
- 2000-05-01 EP EP00928604A patent/EP1175224B1/en not_active Expired - Lifetime
- 2000-05-01 AU AU46815/00A patent/AU776541B2/en not_active Ceased
- 2000-05-01 JP JP2000615025A patent/JP2002543144A/ja not_active Ceased
- 2000-05-01 NZ NZ514519A patent/NZ514519A/en not_active IP Right Cessation
- 2000-05-01 DE DE60018273T patent/DE60018273T2/de not_active Expired - Lifetime
- 2000-05-01 BR BR0010593-7A patent/BR0010593A/pt not_active Application Discontinuation
- 2000-05-01 MX MXPA01011116A patent/MXPA01011116A/es active IP Right Grant
- 2000-05-01 CN CN00807116A patent/CN1349408A/zh active Pending
- 2000-05-01 WO PCT/US2000/011634 patent/WO2000066141A2/en active IP Right Grant
- 2000-05-01 PT PT00928604T patent/PT1175224E/pt unknown
- 2000-05-01 AT AT00928604T patent/ATE289516T1/de not_active IP Right Cessation
- 2000-05-02 PE PE2000000408A patent/PE20010283A1/es not_active Application Discontinuation
- 2000-05-02 AR ARP000102097A patent/AR023824A1/es unknown
- 2000-05-02 TW TW089108323A patent/TWI289454B/zh not_active IP Right Cessation
- 2000-05-02 MY MYPI20001893A patent/MY127670A/en unknown
-
2001
- 2001-10-26 ZA ZA200108870A patent/ZA200108870B/xx unknown
- 2001-11-02 NO NO20015367A patent/NO328679B1/no not_active IP Right Cessation
-
2002
- 2002-02-02 HK HK02100826.8A patent/HK1039278B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2365900A1 (en) | 2000-11-09 |
| AU4681500A (en) | 2000-11-17 |
| WO2000066141A3 (en) | 2001-02-08 |
| HUP0202734A2 (hu) | 2002-12-28 |
| PT1175224E (pt) | 2005-07-29 |
| ZA200108870B (en) | 2003-03-26 |
| AR023824A1 (es) | 2002-09-04 |
| EP1175224A2 (en) | 2002-01-30 |
| TWI289454B (en) | 2007-11-11 |
| DE60018273D1 (de) | 2005-03-31 |
| ATE289516T1 (de) | 2005-03-15 |
| WO2000066141A2 (en) | 2000-11-09 |
| BR0010593A (pt) | 2002-02-13 |
| HK1039278B (zh) | 2005-06-30 |
| CN1349408A (zh) | 2002-05-15 |
| NO20015367D0 (no) | 2001-11-02 |
| JP2002543144A (ja) | 2002-12-17 |
| EP1175224B1 (en) | 2005-02-23 |
| MXPA01011116A (es) | 2002-06-04 |
| NO328679B1 (no) | 2010-04-26 |
| DE60018273T2 (de) | 2005-08-18 |
| ES2238277T3 (es) | 2005-09-01 |
| HK1039278A1 (en) | 2002-04-19 |
| NZ514519A (en) | 2003-07-25 |
| MY127670A (en) | 2006-12-29 |
| NO20015367L (no) | 2002-01-03 |
| AU776541B2 (en) | 2004-09-16 |
| HUP0202734A3 (en) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010283A1 (es) | Composicion que comprende interferon alfa pegilado y un antagonista ccr5 | |
| BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
| BR9910505A (pt) | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c | |
| PE20011348A1 (es) | Agentes antivirales de imidazopiridina e imidazopimiridina | |
| NO20023855D0 (no) | Nukleosidanaloger med karboksamidin-modifisert monosyklisk base | |
| HUP0202593A2 (hu) | Reverz transzkriptáz inhibitor hatású benzofenonok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| BR0108173A (pt) | Composições farmacêuticas de toxina de botulina | |
| BR8706277A (pt) | Composicao ceramica aperfeicoada,corpo ceramico,corpo ceramico composito | |
| EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
| HUP0400365A2 (hu) | 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények | |
| TR200001982T2 (tr) | Farmasötik vurulu salınımlı oral dozaj şekli. | |
| HUP0103283A2 (hu) | Proteázokat gátló pirazinonszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása | |
| BR0113643A (pt) | Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos | |
| HUP0100801A2 (hu) | Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására | |
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| EP2356990A3 (en) | Liposome treatment of viral infections | |
| NZ307089A (en) | Alpha substituted pyrimidine thioalkyl and alkylether compounds and medicaments | |
| MY139203A (en) | Pharmaceutical composition | |
| ATE250080T1 (de) | Hcv ns3 proteaseinhibitoren | |
| NO20011789L (no) | Ribavirin-interferon <alfa> kombinasjonsterapi for utryddelse av påvisbar HCV-RNA i pasienter med kronisk hepatitt C-infeksjon | |
| IL150286A0 (en) | Treatment of dna viral infections | |
| HUP0303364A2 (hu) | Endotelin-antagonista aktivítású aril-alkán-szulfonamidok pirimidinszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| TR200103550T2 (tr) | Faktör VIIa inhibitörler. | |
| PE107599A1 (es) | Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales | |
| BR0108997A (pt) | Terapia imune adjuvante para hiv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |